Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/174053LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
WO 18.08.2022
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/US2022/016143 Applicant IONIS PHARMACEUTICALS, INC. Inventor PRAKASH, Thazha, P.
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one chemical modification.
2.WO/2008/138577MEANS FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
WO 20.11.2008
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/EP2008/003787 Applicant FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. Inventor HORN, Friedemann
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.
3.1990414Means for treating inflammatory diseases, autoimmune diseases and cancer
EP 12.11.2008
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 07009444 Applicant FRAUNHOFER GES FORSCHUNG Inventor HORN FRIEDEMANN
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.
4.WO/2007/058894SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
WO 24.05.2007
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/US2006/043651 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor SAZANI, Peter, L.
Methods and compositions are disclosed for controlling expression of TNF receptors (TNFRl and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-&agr; activity or activity of the relevant ligand. Reducing TNF-&agr; activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-&agr; activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H.
5.1020170119730TNF 수퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질환 치료에 있어서의 그의 용도
KR 27.10.2017
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 1020177029877 Applicant 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Inventor 사자니 피터 엘.
TNF 수용체 (TNFR1 및 TNFR2) 및 TNFR 수퍼패밀리에 속하는 다른 수용체를 암호화하는 pre-mRNA의 스플라이싱을 조절하는 화합물을 이용하여 이들 수용체의 발현을 제어하기 위한 방법 및 조성물이 개시된다. 특히 이러한 화합물들은 상기 수용체의 막횡단 도메인의 제거를 유발하고, TNF-α 활성 또는 관련 리간드의 활성을 감소시키는 길항제로 작용하는 수용체의 가용성 형태를 생산한다. TNF-α 활성을 감소시킴은 TNF-α 활성과 연계된 염증성 질환 또는 증상을 치료 및 개선하는 방법을 제공한다. 마찬가지로, 다른 리간드들과 연계된 질환들도 유사한 방식으로 치료될 수 있다. 특히, 본 발명의 화합물은 스플라이스-스플라이스 스위칭 올리고머 (SSO)로서, 생체내에서 안정한 작은 분자이며, 서열 특이적 방식으로 RNA에 혼성화되고, 그의 표적과 결합하여 알엔아제 H에 의해 분해되지 않는다.
6.WO/2011/117353BIVALENT ANTISENSE OLIGONUCLEOTIDES
WO 29.09.2011
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2011/054545 Applicant MIRRX THERAPEUTICS A/S Inventor MOELLER, Thorleif
The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.
7.1996056659RIBITOL DEHYDROGENASE AND ITS PRODUCTION AND USE
JP 05.03.1996
Int.Class C12N 9/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02Oxidoreductases (1.), e.g. luciferase
04acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Appl.No 1994218155 Applicant HAYASHIBARA BIOCHEM LAB INC Inventor IKUMORI TAKESHI

PURPOSE: To obtain a ribital dehydrogenase having specific physical properties, useful for the transformation of various carbohydrates, with no need of being made to act in a highly purified state, thus useful for foods, cosmetics, medicines, and the chemical industry, etc.

CONSTITUTION: This enzyme, ribitol dehydrogenase, has the following physicochemical properties: activity: when acting on ribitol in the presence of NAD+, D-ribulose is formed, when acting in the presence of NADH, ribitol is formed; substrate specificity: substrate specificity is low, acting on sugar alcohols such as allitol, L-arabitol or L-mannitol as well as ribitol; for such sugar alcohol, the alcohol group on the carbon atom at the 2nd site is oxidized unto keto group in the presence of NAD+ to form a ketose; molecular weight: 20000-30000 (SDS-PAGE), 71000-81000 (gel filtration); isoelectric point: pI 4.4-5.4; activity inhibition: not inhibited at 1mM Ca2+, while inhibited at 1mM Ag2+: optimal temperature: 50-60C in the reaction at pH10 for 1min; optimal pH: 9-10 in the reaction at 30C for 1min; temperature stability: stable up to 30C when preserved at pH10 for 10min.

COPYRIGHT: (C)1996,JPO

8.2009515523TNFスーパーファミリー受容体に対するスプライス切替オリゴマーならびに該オリゴマーを含む医薬組成物
JP 16.04.2009
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
Appl.No 2008540193 Applicant サンタリス ファーマ アー/エス Inventor サザニ、 ペーター エル.

TNF受容体(TNFR1およびTNFR2)ならびにTNFRスーパーファミリーのその他の受容体の発現を、これらの受容体をコードする前駆体mRNAのスプライシングを調整する化合物を使用して制御するための、方法および組成物が開示される。より具体的には、これらの化合物により上記受容体の膜貫通ドメインが除去され、TNF−α活性または関連リガンドの活性を低減するアンタゴニストとして作用する可溶性の受容体が生じる。TNF−α活性を低減することにより、TNF−α活性に関連した炎症性の疾病または状態を治療または改善する方法が提供される。同様に、他のリガンドに関連した疾病も類似の方法で治療することができる。特に、本発明の化合物は、インビボにおいて安定で、RNAに配列特異的にハイブリダイズし、かつその標的と共にRNaseHによる分解を受けない小さな分子である、スプライス−スプライス切替オリゴマー(SSO)である。

9.20170145442Methanogen substrate for biogas production
US 25.05.2017
Int.Class C12P 5/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
5Preparation of hydrocarbons
02acyclic
Appl.No 15313328 Applicant ROQUETTE FRERES Inventor Herve Wyart

The use of a product for internal dehydration of hydrogenated sugar as a methanogen substrate in a method for biogas production, a composition including a monoanhydrohexitol (M), a dianhydrohexitol (D), and anhydrohexitol polymers (P), and a methanisation method.

10.2010017146METHOD FOR PRODUCING AZIDE SUGAR BY MICROORGANISM REACTION AND ENZYME REACTION
JP 28.01.2010
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No 2008181469 Applicant KISHOTO SEISAN GIJUTSU KENKYUSHO:KK Inventor IKUMORI TAKESHI

PROBLEM TO BE SOLVED: To provide a bacterium that belongs to the genus Klebsiella and has ability of producing L-tagatose from galactitol.

SOLUTION: The bacterium of the genus Klebsiella has ability of using 6-azide hexitol as a raw material in which the 6-position of hexose is azidated, oxidizing the 2-position and forming 6-azide ketohexose. Moreover, the bacterium of the genus Klebsiella has ability of isomerizing 6-azide ketohexose and producing 6-azide aldohexose. The 6-azide polyol dehydrogenase is produced by the bacterium, acts on 6-azide polyol and oxidizes the 2-position to give ketose so as to form 6-azide ketohexose. The 6-azide aldose isomerase isomerizes 6-azide ketohexose to produce 6-azide aldohexose.

COPYRIGHT: (C)2010,JPO&INPIT